Byung Ok Kwak

Dr. Byung Ok Kwak

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
AKAram Kwon
Aram Kwon
BKByung Ok Kwak
Byung Ok Kwak
KKKyungmin Kim
Kyungmin Kim
JHJongseok Ha
Jongseok Ha
SKSoo-Jin Kim
Soo-Jin Kim
RLRan Lee
Ran Lee

1 May 2018 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
JHJongseok Ha
Jongseok Ha
JCJieun Choi
Jieun Choi
AKAram Kwon
Aram Kwon
KKKyungmin Kim
Kyungmin Kim
SKSoo-Jin Kim
Soo-Jin Kim
RLRan Lee
Ran Lee

15 March 2022 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
BKByung Ok Kwak
Byung Ok Kwak
YHYoung Jin Hong
Young Jin Hong
DKDong Hyun Kim
Dong Hyun Kim
The Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia. Since the introduction of a universal JE vaccination program and urbanization of Korea, the incidence of JE has dramatically decreased in Korea. However, recent JE cases have occurred, predominantly among unvaccinated adults and with a shift in age distribution. Here we aimed to review the changes in age-specific JE seroprevalence over time and discuss the implications of JE vaccination programs in Korea. Following the last epidemic in 1982–1983, mandatory vaccination for all children aged 3–15 years was conducted annually until 1994. However, JE has reemerged, predominantly affecting unvaccinated adults aged 40 years or older and demonstrating a shift in age distribution toward older populations. The age-specific seroprevalence of the JE virus in Korea has changed noticeably over time. Seropositivity in children and adolescents increased from 10%–59% in the 1970s to 90%–92% in the 1980s after the implementation of the JE vaccination program and increased further to 98% in 2012. No age-specific difference in the seroprevalence of JE was found, and appropriate levels of immunity to JE were maintained for all age groups. Continuous surveillance of the seroprevalence of JE is essential to establish a proper immunization policy in Korea.

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BKByung Ok Kwak
Byung Ok Kwak
JCJi Tae Choung
Ji Tae Choung
YPYong Mean Park
Yong Mean Park
Kwak BO, et al. J Korean Med Sci. 2015 Jan;30(1):60-65. http://dx.doi.org/10.3346/jkms.2015.30.1.60

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJoon Kee Lee
Joon Kee Lee
BKByung Ok Kwak
Byung Ok Kwak
JCJae Hong Choi
Jae Hong Choi
ECEun Young Cho
Eun Young Cho
JKJong-Hyun Kim
Jong-Hyun Kim
DKDong Hyun Kim
Dong Hyun Kim
Lee JK, et al. J Korean Med Sci. 2020 Jun;35(24):e224. https://doi.org/10.3346/jkms.2020.35.e224

15 May 2023 in Clinical and Experimental Pediatrics
Verified
Journal Article
Open access
PDF file
BKByung Ok Kwak
Byung Ok Kwak
BEByungwook Eun
Byungwook Eun
Since coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aimed to evaluate the clinical outcomes and risks of severe COVID-19 in immunocompromised pediatric patients. Previous studies reported that most children and adolescents receiving immunosuppressive medications have clinical presentations and favorable outcomes similar to those of the general pediatric population. Treatments and access to health services should not be interrupted in these populations, and continuous monitoring of the potential impact of variant strains on the risk of immunocompromised pediatric patients is warranted.